Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Cytek Biosciences, Inc. (CTKB)

6.13 -0.17 (-2.70%)
At close: October 30 at 4:00:01 PM EDT
6.13 0.00 (0.00%)
After hours: October 30 at 4:33:26 PM EDT
Trade CTKB on Coinbase
Chart Range Bar
Loading chart for CTKB
  • Previous Close 6.30
  • Open 6.26
  • Bid 4.45 x 200
  • Ask 7.82 x 200
  • Day's Range 6.05 - 6.28
  • 52 Week Range 3.31 - 6.34
  • Volume 1,866,608
  • Avg. Volume 1,205,498
  • Market Cap (intraday) 796.797M
  • Beta (5Y Monthly) 1.16
  • PE Ratio (TTM) --
  • EPS (TTM) -0.62
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 6.17
  • Zacks Rating Neutral

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

cytekbio.com

682

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CTKB
21.39%
S&P 500 (^GSPC)
10.73%

1-Year Return

CTKB
60.47%
S&P 500 (^GSPC)
11.11%

3-Year Return

CTKB
49.51%
S&P 500 (^GSPC)
81.91%

5-Year Return

CTKB
73.13%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 48.14M
Earnings -12.16M
Profit Margin -25.26%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-40M
-20M
0
20M
40M
60M
-60.0%
-40.0%
-20.0%

Analyst Insights

View More

Analyst Price Targets

5.00 Low
6.17 Average
6.13 Current
7.50 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/13/2026
Analyst Stephens & Co.
Rating Action Maintains
Rating Overweight
Price Action Lowers
Price Target 5.5 -> 4.75

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -38.98%

  • Return on Assets (ttm)

    -6.31%

  • Return on Equity (ttm)

    -23.04%

  • Revenue (ttm)

    206.71M

  • Net Income Avi to Common (ttm)

    -80.58M

  • Diluted EPS (ttm)

    -0.62

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    262M

  • Total Debt/Equity (mrq)

    8.22%

  • Levered Free Cash Flow (ttm)

    9.3M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: